Synlogic™ is pioneering the development of a novel class of living Synthetic Biotic™ medicines based on its proprietary drug discovery and development platform. Synlogic’s pipeline includes Synthetic Biotic medicines for the treatment of Phenylketonuria (PKU), Enteric hyperoxaluria, and solid tumors. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as inflammatory and immune disorders. For more information, please visit synlogictx.com.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):